Key terms
About CTXR
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CTXR news
Apr 11
8:34am ET
Citius Pharmaceuticals’ lymphir Phase 1 trial adds City of Hope site
Apr 04
11:03am ET
Biotech Alert: Searches spiking for these stocks today
Mar 20
1:25pm ET
Positive Outlook for Citius Pharmaceuticals with Lymphir’s FDA Resubmission and Market Potential
Mar 18
8:31am ET
Citius Pharmaceuticals: FDA accepts BLA resubmission of LYMPHIR
Feb 23
4:27pm ET
Citius Pharmaceuticals files $250M mixed securities shelf
Feb 23
6:31am ET
Analysts Offer Insights on Healthcare Companies: Minerva Neurosciences (NERV), Citius Pharmaceuticals (CTXR) and Amylyx Pharmaceuticals Inc (AMLX)
Feb 15
2:20pm ET
Analysts Are Bullish on These Healthcare Stocks: Blueprint Medicines (BPMC), Citius Pharmaceuticals (CTXR)
Feb 14
11:05am ET
Buy Rating for Citius Pharmaceuticals Backed by Resubmission of Lymphir BLA and Potential Orphan Drug Exclusivity
Feb 14
8:03am ET
Citius announces resubmission of BLA to FDA forLYMPHIR
Jan 23
4:04am ET
Analysts Offer Insights on Healthcare Companies: Citius Pharmaceuticals (CTXR), Arcus Biosciences (RCUS) and Masimo (MASI)
No recent press releases are available for CTXR
CTXR Financials
Key terms
Ad Feedback
CTXR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CTXR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
